


Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | |
|---|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 09/911,777 |
| | | | Filing Date | 7/24/01 |
| | | | First Named Inventor | Browning et al. |
| | | | Group Art Unit | 1644 |
| | | | Examiner Name | Haddad, Maher |
| | | | Attorney Docket Number | A070 US |
| Sheet | 2 | of | 3 | |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials ¹ | Cite No. ² | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| mH | CA | GRAS et al., "BCMAP: An Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes", International Immunology, Vol. 7, No. 7, 1995, pgs. 1093-1106. | |
| mH | CB | GROSS et al., "TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease", Nature, Vol. 404, April 27 2000, pgs. 995-999. | |
| mH | CC | HAHNE et al., "APRIL, A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth", J. Exp. Med., Vol. 188, No. 6, September 21 1998, pgs. 1185-1190. | |
| mH | CD | KHARE et al., "Severe B Cell Hyperplasia and Autoimmune Disease in TALL-1 Transgenic Mice", Proceedings of the National Academy of Sciences of the United States of America, March 28 2000, Vol. 97, No. 7, pgs. 3370-3375. | |
| mH | CE | KWON et al., "Functions of Newly Identified Members of the Tumor Necrosis Factor Receptor/Ligand Superfamilies in Lymphocytes", Current Opinion in Immunology, 1999, pgs. 340-345. | |
| mH | CF | LAABI et al., "A New Gene, BCM, on Chromosome 16 is Fused to the Interleukin 2 Gene by a t(4;16) (q26;p13) Translocation in a Malignant T Cell Lymphoma", The EMBO Journal, Vol. 11, No. 11, 1992, pgs. 3897-3904. | |
| mH | CG | LAABI et al., "The BCMA Gene, Preferentially Expressed During B Lymphoid Maturation, is Bidirectionally Transcribed", Nucleic Acids Research, Vol. 22, No. 7, 1994, pgs. 1147-1154. | |
| mH | CH | MACKAY et al., "Mice Transgenic for BAFF Develop Lymphocytic Disorders along with Autoimmune Manifestations", Journal of Experimental Medicine, December 6 1999, Vol. 190, No. 11, pgs. 1697-1710. | |
| mH | CI | MALDRY et al., "The Characterization of Murine BCMA Gene Defines it as a New Member of the Tumor Necrosis Factor Receptor Superfamily", International Immunology, Vol. 10, No. 11, 1998, pgs. 1693-1702. | |
| mH | CJ | MUKHOPADHYAY et al., "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue that Activates Apoptosis, Nuclear Factor-kappaB, and c-Jun NH2-Terminal Kinase", Journal of Biological Chemistry, June 4 1999, Vol. 274, No. 23, pgs. 15978-15981. | |
| mH | CK | MOORE et al., "BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator", Science, July 9 1999, Vol. 285, No. 5425, pgs. 260-263. | |

| | | | |
|--------------------|--------------|-----------------|---------|
| Examiner Signature | Maher Haddad | Date Considered | 2/19/03 |
|--------------------|--------------|-----------------|---------|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | | |
|---|---|----|---|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/911,777 |
| | | | | Filing Date | 07/24/2001 |
| | | | | First Named Inventor | Browning et al. |
| | | | | Group Art Unit | 1644 |
| | | | | Examiner Name | Haddad, Maher |
| | | | | Attorney Docket Number | A070 US |
| Sheet | 3 | of | 3 | | |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| mt | CL | PITTI et al., "Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer", Nature, Vol. 396, December 17, 1998, pgs. 699-703. | |
| mt | CM | SCHNEIDER et al., "BAFF, A Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth", J. Exp. Med., Vol. 189, No. 11, June 7 1999, pgs. 1747-1756. | |
| mt | CN | SHU et al., "B Cell Maturation Protein is a Receptor for the Tumor Necrosis Factor Family Member TALL-1", PNAS, Vol. 97, No. 16, August 1 2000, pgs. 9156-9161. | |
| mt | CO | THOMPSON et al., "BAFF Interacts with the Orphan Receptor, BCMA", Scandinavian Journal of Immunology, Vol. 51 (Supplement 1), 2000, pg. 65. | |
| mt | CP | THOMPSON et al., "BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population", J. Exp. Med., Vol. 192, No. 1, July 3 2000, pgs. 129-135. | |
| mt | CQ | XIA et al., "TACI is a TRAF-Interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation", J. Exp. Med., Vol. 192, No. 1, July 3 2000, pgs. 137-143. | |
| mt | CR | YU et al., "APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity", Nature Immunology, Vol. 1, No. 3, September 2000, pgs. 252-256. | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--------------|-----------------|---------|
| Examiner Signature | Maher Haddad | Date Considered | 2/19/03 |
|--------------------|--------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.